ON 01910.Na
ON 01910.Na is a pharmaceutical drug with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Clinical Trials (9)
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9